
What smart money is saying about Bonesupport
1 fund in our archive has pitched Bonesupport — most recently Goodhart European Fund in March 2026.
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
Get an email when a fund writes about it
Position history
Between Q1 2026 and Q2 2026, 1 fund letter reported a position in Bonesupport, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q1 2026 | 0 | 0 | 0 | 1 |
Fund activity · 1 position
- HoldsGoodhart Partners Global Future Leaders FundJune 2026
“Bonesupport and Kuros Biosciences both had a weak quarter in share price terms, but we have not seen a single downgrade to consensus estimates or company guidance for either business.”
Read the letterBonesupport
Fund coverage · 1 thesis
- Goodhart European FundMarch 2026
Bonesupport is an orthobiologics company with a differentiated injectable bioceramic and long-term growth potential at a more acceptable valuation.
Read the full thesis
Read every full thesis on Bonesupport
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→